Unassociated Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of earliest event reported: June 2, 2008

CLEVELAND BIOLABS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-32954
 
20-0077155
(State or other jurisdiction
of incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer
Identification Number)

73 High Street, Buffalo, New York 14203
(Address of principal executive offices)

Registrant’s telephone number, including area code: (716) 849-6810
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 1.01  Entry into a Material Definitive Agreement.

On June 2, 2008, Cleveland BioLabs, Inc. (the “Company”) entered into a new Consulting Agreement (the “Agreement”) with the Company’s Chief Scientific Officer, Dr. Andrei Gudkov. The Agreement supersedes Dr. Gudkov’s previous consulting agreement with the Company, dated August 1, 2004. Under the Agreement, Dr. Gudkov will continue to provide strategic leadership for all projects of the Company. A copy of the Agreement is attached hereto as Exhibit 10.1.

Item 9.01  Financial Statements and Exhibits.
 
(d)
Exhibits

Exhibit No.
Exhibit
10.1
Consulting Agreement between Cleveland BioLabs, Inc. and Andrei Gudkov, dated as of June 2, 2008


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
CLEVELAND BIOLABS, INC.
  
 
        
Date: June 5, 2008
By:
 
/s/ Michael Fonstein
  
 
 
 
Michael Fonstein
  
 
 
 
President and Chief Executive Officer
  

 
EXHIBIT INDEX

Exhibit No.
Exhibit
10.1
Consulting Agreement between Cleveland BioLabs, Inc. and Andrei Gudkov, dated as of June 2, 2008